

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berrī Chhara Road, P.O. Tanda Herī, Tehsil Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

Date: 11th November, 2020

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Submission of Outcomes of Board Meeting and Un-Audited Financial Results for the quarter and half year ended 30th September, 2020

1. Intimation and disclosure under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Un-Audited Financial Results and Limited Review Report for the quarter and half year ended 30.09.2020
2. Take note of the Resignation of Mrs. Monisha Meghna (Membership No. A41747), Company Secretary and Compliance Officer of the Company with effect from 07.10.2020

Dear Sir/ Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Archies Limited ("Company") in its meeting held today approved the Un-Audited Financial Results (Standalone) for the Quarter and half year ended 30th September, 2020 of the Company as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal.

Further due to the applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Companies Act, 2013, following approvals has been accorded in Board Meeting held today:

1. Take note of the Resignation of Mrs. Monisha Meghna (Membership No. A41747), Company Secretary and Compliance Officer of the Company with effect from 07.10.2020

The above information will also be available on the Company's Website, www.genomicvalley.com.

The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 04:30 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited



Yogesh Agrawal
Managing Director
DIN: 01165288
Add: G-74, Pushkar Enclave,
Paschim Vihar Delhi – 110063

LIMITED REVIEW REPORT

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil-Bahadurgarh, District-Jhajjar, Haryana-124507.

Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter and Half Year ended on 30th September, 2020

We have reviewed the accompanying statement of unaudited financial results for **the quarter and half year ended September 30, 2020** ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For ANDROS & CO.
Chartered Accountants

Bhavuk Garg

(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

Place: Delhi
Date: 11.11.2020

GENOMIC VALLEY BIOTECH LIMITED

Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,

TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507


CIN: L01122HR1994PLC033029

Genomic Valley Biotech Limited today reported its financial performance for the quarter and six months ended

30 September 2020

Statement of Standalone Un-Audited Financial Results as compared to the previous quarter and year are:

Sr. No.	Particular	In Rs.					
		3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for corresponding period ended	Previous year ended
		30-Sep-20 Un-Audited	30-Jun-20 Un-Audited	30-Sep-19 Un-Audited	30-Sep-20 Un-Audited	30-Sep-19 Un-Audited	31-Mar-20 Audited
I	Revenue From Operations	669,690	277,600	1,812,800	947,290	3,693,129	8,465,629
II	Other Income	-	-	122,504	-	125,669	140,869
III	Total Revenue (I+II)	669,690	277,600	1,935,304	947,290	3,818,799	8,606,499
IV	Expenses						
	Cost of materials consumed	8540	-	0	8,540	16,265	88,265
	Purchases of Stock-in-Trade	-	-	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	765,600	-	765,600	-	-765,600
	Employee benefits expense	194,444	325,490	365,892	519,934	1,287,759	1,765,260
	Financial costs	-	-	-	-	-	1,798,878
	Depreciation and amortization expense	481,439	481,439	334,578	962,878	806,801	1,785,802
	Other expenses	248,963	59,879	1,013,781	308,842	1,375,057	1,876,582
	Total Expenses (IV)	933,386	1,632,408	1,714,251	2,565,794	3,485,882	6,549,188
V	Profit / (Loss) before exceptional item and tax (III-IV)	-263,696	-1,354,808	221,053	-1,618,504	332,917	2,057,311
VI	Exceptional Item	-	-	-	-	-	-
VII	Profit/loss before Tax (V-VI)	-263,696	-1,354,808	221,053	-1,618,504	332,917	2,057,311
VIII	Tax expenses						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	-802,616
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	-263,696	-1,354,808	221,053	-1,618,504	332,917	2,859,927
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	-263,696	-1,354,808	221,053	-1,618,504	332,917	2,859,927
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	-263,696	-1,354,808	221,053	-1,618,504	332,917	2,859,927
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500
XVII	Earning Per Equity Share (for continuing operation):						
	1) Basic	-0.09	-0.44	0.07	-0.53	0.11	0.94
	2) Diluted	-0.09	-0.44	0.07	-0.53	0.11	0.94
XVIII	Earning Per Equity Share (for discontinued operation):						
	1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):						
	1) Basic	-0.09	-0.44	0.07	-0.53	0.11	0.94
	2) Diluted	-0.09	-0.44	0.07	-0.53	0.11	0.94



Statement of Asset and Liabilities

Particulars	Current half year ended		Previous year ended	
	30/09/2020		31/03/2020	
	Un-Audited		Audited	
	Standalone		Standalone	
ASSETS				
Non Current Assets				
Property, plant and equipment	59,516,484		44,686,362	
Capital work in progress	4,879,339		4,879,339	
Other Intangible assets	-		-	
Intangible assets under development	-		-	
Financial assets	-		-	
Investment	-		-	
Loans	5,950,000		25,600,000	
Security Deposits	200,000		200,000	
Other financial assets	-		-	
Deferred tax assets (Net)	653,183		653,183	
Other non current assets	-		-	
Total Non-Current Assets	71,199,006		76,018,884	
Current Assets				
Inventories	474,023		1,239,623	
Financial Assets:	-		-	
Investments	-		-	
Trade Receivables	668,092		1,026,692	
Cash and Cash equivalents	308,780		319,100	
Other Balances with banks	6,094		58,454	
Loans	-		-	
Other financial assets	-		-	
Other Current assets	1,757,707		1,400,361	
Total Current Assets	3,214,695		4,044,230	
Total Assets	74,413,701		80,063,114	
EQUITY AND LIABILITIES				
Equity				
Equity Share Capital	30,545,000		30,545,000	
Othe Equity	18,306,655		19,925,159	
Total Equity	48,851,655		50,470,159	
Non Current Liabilities				
Financial liabilities				
Borrowings	14,788,077		14,788,077	
Security Deposits	-		-	
Other Financials liabilities	-		-	
Deferred tax liabilities (Net)	-		-	
Provisions	-		-	
Other Non Current liabilities	7,120,000		7,120,000	
Total Non Current Liabilities	21,908,077		21,908,077	
Current Liabilities				
Financial liabilities				
Borrowings	-		-	
Trade Payables	157,592		639,363	
Other Financials liabilities	-		-	
Provisions	76,860		121,860	
Other Current liabilities	3,419,517		6,923,655	
Total Current Liabilities	3,653,969		7,684,878	
TOTAL EQUITY AND LIABILITIES	74,413,701		80,063,114	



CASH FLOW STATEMENT FOR THE PERIOD ENDED 30 SEPTEMBER, 2020

Particulars	Amount in INR		
	30.09.2020	30.09.2019	31.03.2020
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit As Statement Profit & Loss	-1,618,504	332,917	2,057,310
Adjustment For			
Discount received	-	-318	-
Non-Operating Income	-	-	-
Interest Income	-	-21,851	-21,851
Loss on sale of assets	-	-	-
Depreciation and Amortisation Expenses	962,878	806,801	1,785,803
Operating Profit Before Change in Working Capital	-655,626	1,117,549	3,821,262
ADJUSTMENTS FOR WORKING CAPITAL:			
Increase/Decrease in Loans and Advances	19,650,000	-5,000,000	-5,000,000
Increase/ Decrease in Inventories	765,600	-36,107	-52,182
Increase/Decrease in Security Deposits	-	-	-
Increase/Decrease in Trade Receivables	358,600	70,001	-443,209
Increase/Decrease in Other Current Assets	-357,346	-336,510	-909,180
Increase/Decrease in Current Liabilities	-4,030,909	4,387,806	6,957,383
CASH GENERATED FROM OPERATIONS	15,730,320	202,739	4,374,074
Taxes Paid			
Total (A)	15,730,320	202,739	4,374,074
B. CASH FLOW FROM INVESTING ACTIVITIES			
Additions/Sales to fixed assets	-15,793,000	-719,429	-4,769,015
Purchase/Sell of Investments	-	-	-
Discount received	-	318	-
Non-Operating Income	-	-	-
Interest Income	-	21,851	21,851
Total (B)	-15,793,000	-697,260	-4,747,164
C. CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from Borrowings	-	-100,000	-
Preliminary Expenses	-	-	-
Total (C)	-	-100,000	-
NET CASH FLOWS DURING THE YEAR (A+B+C)	-62,680	-594,521	-373,090
Cash and Cash Equivalents (Opening Balance)	377,554	750,644	750,644
Cash and Cash Equivalents (Closing Balance)	314,874	156,123	377,554


Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on 11.11.2020. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment i.e. Floriculture in terms of Ind-AS 108 on Segment Reporting.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited

Place : Delhi
Dated : 11.11.2020




Yogesh Agrawal
 (Managing Director)
 DIN-01165288

Add: G-74 Pushkar Enclave
Paschim Vihar, New Delhi-110063